MDGL
$499.40-0.06%
as of close, Oct 2, 2026
☾ AH $499.40 -0.06%
Madrigal Pharmaceuticals Inc.Stock · Health CareNasdaq Composite 0.02%Russell 1000 0.01%US Stock Market 0.01%Russell 3000 0.01%
MDGL — Madrigal Pharmaceuticals Inc. price, chart and key statistics
Technical analysis2
Overlay lines0
Addendum charts0
VolumeEEEE
100.0200.0300.0400.0500.005.0M10.0M$499.40—20162019202120242026
2026-10-02
Price$499.40
MA20$523.93
MA50$491.50
Vol1.5M
Key stats
Price data
- Price
- $499.40
- Change YTD
- -14.24%
- Next earnings
- Nov 3, 2026
- Market cap
- 11.5B
- Enterprise value
- 10.8B
- Shares outstanding
- 23.1M
- 52W low
- $393.61
- 52W high
- $615.00
- From 52W high
- -18.80%
- From 52W low
- +26.88%
- 52W range
- 48%
- Beta
- -0.97
Volume
- Rel volume
- 1.29×
- 30D volume
- 223.7K
- 30D $ vol
- 117.6M
Insider trading
- Insider net 1W
- none
- Insider net 1M
- −$6.2M
- Insider net 3M
- −$7.9M
- Insider net 1Y
- −$40.2M
Form 4 transactions by trade date, as filed; latest on file 2026-09-11.
Fundamentals
- Sales (ttm)
- 1.3B
- Sales/share
- $55.57
- EPS (ttm)
- -$11.26
- FCF (ttm)
- -206.3M
- FCF/share
- -$8.93
- Book value/share
- $22.67
- Net margin
- -25.32%
- ROE
- -62.07%
- ROA
- -26.12%
- Debt / equity
- 0.65×
- Current ratio
- 3.20
Growth (CAGR, ttm) · 10Y
- Sales
- +149.20%n/an/an/a
- Shares
- +3.66%+7.74%+6.84%+19.36%
Per-share growth (CAGR, ttm) · 10Y
- Sales/share
- +140.40%n/an/an/a
- Book value/share
- -27.42%+59.32%+6.81%+7.94%
- Price
- +11.07%+51.58%+44.05%+44.37%
- Total return
- +11.07%+51.58%+44.05%+44.37%
Fundamentals end at the last reported quarter; price and total return end at the latest close.
Valuation
- P/E (ttm)
- -44.4×
- Fwd P/E
- 53.0×
- P/S (ttm)
- 9.0×
- P/B (mrq)
- 22.0×
- EV/Sales (ttm)
- 8.4×
- FCF yield (ttm)
- -1.79%
- Buyback yield (realized, 1y)
- -3.66%
- Shareholder yield (realized, 1y)
- -3.66%
- Buyback yield (cash, ttm)
- 0.00%
- Shareholder yield (cash, ttm)
- 0.00%
Vs own 10Y history
- P/S
- 0th
- P/B
- 83rd
Bar = where today’s multiple sits in MDGL’s own 10-year range:near a decade-low (cheap)→near a decade-high (rich).
Performance · price return · as of 2026-10-02
1D
-0.06%
5D
-3.32%
1M
-8.69%
3M
-5.43%
YTD
-14.24%
1Y
+11.07%
5Y
+520.76%
Recent filings
- Sep 11Insider sale · Sibold William John (President and CEO · Director) sold 5,221 shares for $2.8M at $533.09–$546.38 under a 10b5-1 plan
- Sep 9Insider sale · Sibold William John (President and CEO · Director) sold 6,362 shares for $3.4M at $527.88–$542.55 under a 10b5-1 plan
- Aug 17Insider sale · Kelley Shannon T (General Counsel) sold 664 shares for $342K at $514.97
- Aug 128-K · Directors or officers; compensation; Regulation FD disclosure
- Jul 30Earnings · Earnings release — EPS −$1.99 vs −$2.55 est. (+22.0%); revenue $364.3M (+71% y/y) 9.8%
Financial statements
Open full MDGL financials →Loading financial statements…
Related Health Care
| Ticker | Name | 1M | 1D |
|---|---|---|---|
| NVS | Novartis AG | -13.21% | -0.04% |
| NVO | Novo Nordisk A/S | -20.21% | -0.21% |
| SNY | Sanofi ADS | -10.23% | -1.84% |
| GSK | GSK plc American Depositary Shares (Each representing two Ordinary Shares) | -6.76% | -0.32% |
| NTRA | Natera Inc. | +26.20% | +0.46% |
| ARGX | argenx SE American Depositary Shares | -12.90% | -1.79% |
| TAK | Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) | -3.09% | +0.00% |
| TEVA | Teva Pharmaceutical Industries Limited American Depositary Shares | +5.44% | +0.56% |
